Neurological Biomarker Market Report (2022-2030) – Abbott Laboratories, Qiagen, ACOBIOM, DiaGenic ASA, Olink Biosciences

PUNE, Jan. 9, 2023 (GLOBE NEWSWIRE) — According to a new market research report, “Neurological biomarker market By type (genomics, metabolomics, proteomics, imaging), by application (Alzheimer’s disease, Parkinson’s disease, multiple sclerosis), by end-user (hospitals and laboratories, independent diagnostic centers, research institutions) – Global Outlook & Forecasts 2022-2030 Neurological Biomarker Market Published by Growth Plus Reports CAGR 11.9% from 2021 US$17.88 billion by 2030.

Download the PDF Brochure of Neurological biomarker market Size – Global Analysis by COVID-19 Impact and Strategic Developments:

https://growthplusreports.com/inquiry/request-sample/neurological-biomarkers-market/8040

market driver

The major driver of the global neurological biomarkers market is the increasing incidence of neurological disorders such as dementia, Alzheimer’s disease, Parkinson’s disease, brain trauma and migraine headaches. In addition, growing demand for minimally invasive testing methods and early detection of neurological diseases is contributing to the expansion of the global market. The need for neurological biomarkers is increasing due to their ability to speed up drug development. Similarly, the use of biomarkers in confirming diagnoses, determining treatment, and tracking disease progression is fueling the expansion of the global market. Furthermore, the demand for neuronal biomarkers is increasing due to new developments such as bio-hi marker clusters and biomarker signatures. Also, continued investment in research and development by large companies is projected to accelerate the expansion of the global neurological markers market.

The global neurological biomarkers market is analyzed from four perspectives: type, application, end-user, and region.

excerpt from “Segmentation by type”

Based on type, the global neurological biomarkers market is segmented into:

story continues

• genome

• metabolomics

• proteomics

• imaging

The proteomics segment will hold the largest market share in the global neurological biomarkers market in 2021. For biomarker development, proteomic analysis provides detailed protein profiling of tissues, plasma, serum, and cerebrospinal fluid (CSF). It therefore plays an integral role in the growth of the segment. In addition, quantitative proteomics tools that can rapidly and accurately measure hundreds of proteins from small sample sizes have increased the demand for proteomics. In addition, proteomics enables the development of biomarkers using established mass spectrometry-based platforms and more recent platforms such as multiplexed immunoassays and aptamer methods, thereby identifying disease-associated protein changes and to drive growth in the segment.

excerpt from Application segmentation

Based on application, the global neurological biomarkers market is segmented into:

• Alzheimer’s disease

• Parkinson’s disease

• multiple sclerosis

Alzheimer’s disease dominates the global neurological biomarker market, capturing the largest market share in 2021. A large portion of the Alzheimer’s disease segment can be largely attributed to the overall increased prevalence. Alzheimer’s disease is the most common type of neurodegenerative disease. According to WHO, approximately 55 million people worldwide have dementia, of which Alzheimer’s disease accounts for approximately 60% to 70% of all cases. Additionally, government and non-governmental organizations are funding Alzheimer’s disease-related research and development, which is expected to boost the expansion of the segment.

Excerpt from “By Region Segmentation”

Based on region, the global neurological biomarkers market is segmented as follows:

• North America

• Europe

• Asia Pacific

• the rest of the world

North America will dominate the global neurological biomarkers market in 2021, followed by Europe. The Asia-Pacific market is expected to grow at the fastest CAGR during the forecast period. A large share of this region is attributed to the increasing incidence of neurological diseases. According to the Centers for Disease Control and Prevention (CDC), approximately 6.5 million people in the United States have Alzheimer’s disease. Alzheimer’s disease is one of the top 10 causes of death in the United States. Additionally, increasing R&D funding for neurological biomarkers in the region is fueling the region. Regional expansion. Key market players are present in the region and government initiatives to raise public awareness of neurological disorders are also expected to boost growth in the region.

Excerpt from “Competitive Landscape”

The prominent players operating in the global neurological biomarkers market are:

View a detailed overview of the research report using TOC:
https://growthplusreports.com/report/neurological-biomarkers-market/8040

table of contents

1. Foreword

   1. market ecosystem

   2. timeline under consideration

      1. Historic year – 2020

      2. Base Year – 2021

      3. Forecast Years – 2022 to 2030

   3. Currency used in reports

2. research method

   1. research approach

   2. Data collection method

   3. data source

      1. secondary source

      2. primary source

   4. Market estimation approach

      1. bottom up

      2. top down

   5. Market forecast model

   6. Limitations and Assumptions

3. Premium Insight

   1. Current Market Trends (COVID-19 Perspective)

   2. Key Players and Competitive Positioning (2021)

4. market dynamics

   1. driver

   2. restraint/challenge

   3. chance

5. Global Neurological Biomarker Market – Analysis and Forecast by Type

   1. genome

   2. metabolomics

   3. proteomics

   4. imaging

   5. others

6. Global Neurological Biomarker Market – Analysis and Forecast by Application

   1. Alzheimer’s disease

   2. Parkinson’s disease

   3. multiple sclerosis

   4. others

Report scope:

Value proposition related to the report:

• Featuring free analyst time and expert interviews for each report

• Comprehensive quantitative and qualitative insights at segment and subsegment level

• Covid 19 impact trends and outlook

• Detailed insights at global/regional/country level

• Deep insight into market dynamics (drivers, constraints, opportunities) and business environment

• Comprehensive coverage of the competitive environment

• victory conditions

• Exhaustive coverage on “strategic developments” registered by key players in the market

Customization options:

• Distributor Landscape Assessment

• Pipeline evaluation

• price intelligence

• Customer base evaluation

• Analysis of investments and initiatives

• “Business Profiles” of Key Players

Buy directly a premium copy of Neurological Biomarkers Market Growth Report (2022-2030): https://growthplusreports.com/checkout?_token=WHuocJKe4tQgoVEJ1wkPm2mDhYiHgdXWIqpAgXgp&report_id=8040&license=Single

about us

Growth Plus Reports is part of GRG Health, a global healthcare knowledge services company. We are proud to be members of the EPhMRA (European Pharmaceutical Marketing Research Association).

Growth Plus’ portfolio of services leverages our core capabilities of secondary and primary research, market modeling and forecasting, benchmarking, analytics, and strategy development to provide scalable, breakthrough solutions that prepare our clients for future growth and success. help you create a

We have been honored as “Most Innovative Healthcare Market Research Firm in 2020” by the prestigious CEO Magazine.

CONTACT: Manan Sethi Director, Market Insights Email: enquire@growthplusreports.com Phone no: +91 96545 76783 Web: https://growthplusreports.com/